Emerging biotech company, Kraig Biocraft Laboratories, Inc. was founded by the inventor of the company’s technology, current chief executive officer, Kim Thompson. The company is a fully reporting organization and trades on the over-the-counter market under the stock symbol KBLB. As of last report, there are about 501 million common shares outstanding, with approximately 64% held by the chief executive officer.

Kraig Biocraft Laboratories’ CEO serves as the overall coordinator for the company relative to business operations and ongoing research and development. Several prominent genetic scientists have significantly developed the companies’ technologies. Additionally, the laboratory staffs of these professors are also making significant contributions to the company’s efforts.

Kraig Biocraft Laboratories, Inc. has a developed intellectual portfolio relating to the harvesting of silk from genetically modified silkworms. The company brings together preeminent researchers in a collaborative effort to produce commercially significant quantities of

Kraig Biocraft Laboratories, Inc. announced that Dr. Malcolm Fraser, Dr. Wang, Dr. Sohn and other members of the scientific team are preparing for the genetic insertion of recently created DNA constructs. The genetic constructs are customized packets of DNA that provide genetic instructions for the creation of new polymers and spider silk-based proteins. These unique genetic insertion packets include several that are specifically designed for the production of new fusion silk proteins.

CEO Kim K. Thompson stated, “These constructs include a number of new DNA combinations that are truly exciting. The increases in laboratory productivity over the last eight months are now enabling us to do more and to do it faster. This number of unique genetic constructs is a new breakthrough for the Company. Each of these constructs has the potential to result in the development of a new polymer or high performance fiber.”

We have been covering Kraig Biocraft Laboratories since December of last year. Those who have read our articles understand why we are excited about this company’s prospects to develop a “super fiber” that can be sold into the technical textiles industry. This super fiber, spider silk, has truly remarkable properties and may have numerous commercial and consumer applications.

Currently Kraig Biocraft is in the research and development stage, but has been making excellent progress in the labs and is now capable of accomplishing five thousand genetic transfers in a single week using its newly designed DNA insertion packets. Additional lab personnel and a change in techniques has significantly boosted productivity and the company’s odds of success.

Artificial or transgenic production of spider silk will surely be viewed by the scientific community as a major breakthrough. Such a development would also likely yield significant coverage in the

Both existing and potential investors of Kraig Biocraft Laboratories Inc (KBLB.OB) should understand that they have one of the most pioneering and accomplished minds in the field of genetic engineering working in their corner. This member of Kraig’s Scientific Advisory Board, Dr. Malcolm Fraser, presides over the University of Notre Dame’s transgenic-based laboratory which has currently been focusing on developing “spider silk” polymers.

Since Kraig and Notre Dame have partnered in a collaboration agreement, essentially exchanging funding for both R&D data and intellectual property rights, Kraig is uniquely positioned to benefit from the work conducted under Dr. Fraser at Notre Dame. Consequently, the company’s stock performance will be heavily tied to Dr. Fraser’s breakthroughs in the laboratory.

Considering Kraig’s track record, investors should feel at ease with the notion that his work can single handedly affect Kraig’s stock price. Shortly after the

Earlier this month, Kraig Biocraft Laboratories announced that its scientific team, including Dr. Malcolm Fraser, Dr. Wang, Dr. Sohn, and other members, have found a process capable of doubling the number of gene transfers performed, greatly increasing productivity of the spider silk and high performance polymer development program.

Kraig Biocraft is focused on developing and commercializing high performance polymers using spider silk gene sequences. The company intends to participate in the $92 billion market for high performance and technical fibers. Last year, Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame and has since then been a proud sponsor of scientific research within the university.

CEO Kim K. Thompson commented, “Until recently, we were performing approximately 200 to 400 micro-injections for DNA transfer on a weekly basis. With the huge increase in brain-power that resulted from the

Headquartered in Lansing, Michigan, Kraig Biocraft Laboratories, Inc. is a biotechnology company focusing on the development of commercially significant polymers and high performance fibers. The Company works with university scientists and laboratories to create new polymers with potentially broad applications. Spider silk gene sequences are at the core of Kraig Biocraft’s technology.

Spider Silk is one of the strongest fibers produced in nature. Dragline silk, the silk used when a spider is repelling, is of commercial interest. This natural polymer is extremely strong and extremely flexible. These properties of the underlying polymer create the potential for commercial opportunities. Kraig Biocraft has the exclusive right, for the spider silk gene sequences in their field of research. Dr. Lewis of the University of Wyoming first studied and then patented these genetic sequences. The Company obtained, in 2006, certain exclusive rights from the University to utilize the sequences in their field of